Groundbreaking weight-loss drugs like Ozempic and Wegovy have understandably generated a lot of excitement, bringing hope to ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

A study suggests that GLP-1 agonist drugs, like Ozempic, may reduce overdose risks and aid in addiction treatment. Further ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Weight-loss medications surged in popularity this year. A survey from Kaiser Family Foundation found one in eight adults have ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Elon Musk has revealed he has upgraded from Ozempic to Mounjaro, nicknamed the “King Kong” of weight-loss drugs, in a photo ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.

Research backs this up: Young men who consumed more protein while losing weight and on an intense exercise regiment gained ...